US4337254A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions
Assignee: SmithKline Beecham Corp
•
Filing: 1978-05-18
•
Granted: 1982-06-29
•
Expires: 1998-05-18
Abstract
Abstract Pharmaceutical combinations comprising (a) prostacyclin, dihydroprostacyclin or a pharmaceutically acceptable salt of either of these, and (b) a phosphodiesterase inhibitor. Pharmaceutical formulations comprising a combination as above and a pharmaceutically acceptable carrier. Methods are disclosed for preparing the combinations and the formulations. The combinations and formulations are useful for preventing or minimizing platelet aggregation in blood, blood products or blood substitutes for example in the treatment of thrombosis, gastric lesions and wounds, and in the extra-corporeal circulation of blood and in blood separation processes.
Inventors
- 👤 Salvador E. Moncada
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 03:04
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/335; A61K31/34; A61K31/435; A61K31/47; A61K31/519; A61K31/52; A61K31/55; A61K31/557
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
108 words
A method for preventing the lowering of blood pressure in mammals while at the same time inhibiting the aggregation of blood platelets in said mammals, said method comprising internally administrating to said mammal, simultaneously or sequentially, 1 part by weight of: (a) prostacyclin, a pharmaceutically acceptable salt of prostacyclin; dihydroprostacyclin, or a pharmaceutically acceptable salt of dihydroprostacyclin; and 1 to 200 parts by weight of (b) theophylline, 3 isobutyl-1-methyl xanthine, dipyridamole, a pharmaceutically acceptable salt of theophylline, a pharmaceutically acceptable salt of dipyridamole, or a pharmaceutically acceptable salt of 3 isobutyl-1-methyl xanthine; to prevent lowering of blood pressure while at the same time inhibiting aggregation of blood platelets.
Claim 2
Independent Claim
108 words
A method for preventing the lowering of blood pressure in mammals while at the same time inhibiting the aggregation of blood platelets in said mammals, said method comprising internally administrating to said mammal, simultaneously or sequentially, 1 part by weight of: (a) prostacyclin, a pharmaceutically acceptable salt of prostacyclin; dihydroprostacyclin, or a pharmaceutically acceptable salt of dihydroprostacyclin; and 1 to 200 parts by weight of (b) theophylline, 3 isobutyl-1-methyl xanthine, dipyridamole, a pharmaceutically acceptable salt of theophylline, a pharmaceutically acceptable salt of dipyridamole, or a pharmaceutically acceptable salt of 3 isobutyl-1-methyl xanthine; to prevent lowering of blood pressure while at the same time inhibiting aggregation of blood platelets.
Claim 3
Dependent Claim
11 words
The method of claim 1 in which sodium prostacyclin is administered.
Claim 4
Dependent Claim
10 words
The method of claim 1 in which theophylline is administered.
Claim 5
Dependent Claim
10 words
The method of claim 2 in which theophylline is administered.
References Cited (Backward Citations)
US4051236A
Cited
DE2431558A1
Cited
US3962243A
Cited
US4009282A
Cited
US3954787A
Cited
US3998953A
Cited
US4158667A
Cited
DE2739277C2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-06-28 | 1985-12-28 | 1986-06-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-06-28 | 1989-12-28 | 1990-06-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-06-28 | 1993-12-28 | 1994-06-29 | $7700.00 | Window Closed / Lapsed |